S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.38 (-1.47%)
BABA   72.14 (-0.26%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+10.74%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.51%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.38 (-1.47%)
BABA   72.14 (-0.26%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+10.74%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.51%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.38 (-1.47%)
BABA   72.14 (-0.26%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+10.74%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.51%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.38 (-1.47%)
BABA   72.14 (-0.26%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+10.74%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.51%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)

Flexion Therapeutics Stock Price, News & Analysis (NASDAQ:FLXN)

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$9.12
▼
$9.12
50-Day Range
$9.12
▼
$9.44
52-Week Range
$4.30
▼
$13.66
Volume
N/A
Average Volume
1.18 million shs
Market Capitalization
$458.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

FLXN stock logo

About Flexion Therapeutics Stock (NASDAQ:FLXN)

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.


FLXN Stock News Headlines

November 24, 2023 | benzinga.com
SpringWorks Therapeutics Stock (NASDAQ:SWTX), Analyst Ratings, Price Targets, Predictions
July 11, 2023 | benzinga.com
Flexion wins MCADS contract to modernize CMS Claims Handling System
December 8, 2023 | Wealthpress (Ad)
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
July 10, 2023 | finance.yahoo.com
Flexion achieves Select Tier Status within the AWS Partner Network
June 10, 2023 | yahoo.com
7 Exercises to Stretch Plantar Flexion Movement
May 16, 2023 | marketwatch.com
2023-2029 Flexion Tires Market Growth Prospects and Countries Analysis | with 91 Pages
May 4, 2023 | finance.yahoo.com
OPPO Find N2 Flip's Flexion Hinge Marks A Breakthrough In Flip Phone Experience
April 28, 2023 | marketwatch.com
Prone Leg Flexion Trainers Market Global Outlook and Projection till 2029
December 8, 2023 | Wealthpress (Ad)
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
April 12, 2023 | marketwatch.com
Abdominal Flexion Training Device Market Research & Size Analysis 2023-2028
April 6, 2023 | marketwatch.com
Prone Leg Flexion Trainers Market 2023 Huge Demand, Growth Opportunities and Expansion by 2031
March 23, 2023 | marketwatch.com
Global Flexion Tires Market: Future Extrapolations and Emerging Updates for 2023-2027
February 24, 2023 | msn.com
Oppo’s new Flexion hinge has made flip phones more practical and crease minimal
September 21, 2022 | seekingalpha.com
PCRX Pacira BioSciences, Inc.
September 1, 2022 | thestreet.com
Coherus BioSciences Inc. News
August 17, 2022 | venturebeat.com
Flexion targets TikTok influencers on behalf of game developers
July 2, 2022 | thestreet.com
Biotech Movers: Akebia Soars on Expanded Partnership With Otsuka
January 13, 2022 | thestreet.com
Why Flexion Therapeutics (FLXN) Stock Is Plummeting in After-Hours Trading Today
November 3, 2021 | finance.yahoo.com
Pacira's (PCRX) Q3 Earnings Beat Estimates, Revenues Miss Mark
November 1, 2021 | finance.yahoo.com
SHAREHOLDER ALERT: WeissLaw LLP Reminds DWSN, PAE, XLRN, and FLXN Shareholders About Its Ongoing Investigations
October 30, 2021 | finance.yahoo.com
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Flexion Therapeutics, Inc. - FLXN
October 30, 2021 | prnewswire.com
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Flexion Therapeutics, Inc. - FLXN
October 27, 2021 | finance.yahoo.com
Earnings Preview: Flexion Therapeutics (FLXN) Q3 Earnings Expected to Decline
October 21, 2021 | finance.yahoo.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ESBK, FLXN, COLB, CXP; Shareholders are Encouraged to Contact the Firm
October 13, 2021 | finance.yahoo.com
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Flexion Therapeutics, Inc. (Nasdaq - FLXN)
October 13, 2021 | nasdaq.com
Flexion Therapeutics (NASDAQ:FLXN) shareholders are up 53% this past week, but still in the red over the last five years
October 13, 2021 | marketwatch.com
Flexion Therapeutics Shares Soar on Pacira BioSciences Deal >FLXN
See More Headlines
Receive FLXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Flexion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/12/2021
Today
12/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FLXN
CUSIP
N/A
CIK
1419600
Web
www.flexiontherapeutics.com
Phone
(781) 305-7777
Fax
781-202-3399
Employees
257
Year Founded
2007

Profitability

EPS (Most Recent Fiscal Year)
($2.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-113,710,000.00
Net Margins
-100.32%
Pretax Margin
-100.32%
Return on Equity
N/A
Return on Assets
-44.26%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.38
Quick Ratio
4.05

Sales & Book Value

Annual Sales
$85.55 million
Price / Sales
5.36
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.34) per share
Price / Book
-26.82

Miscellaneous

Outstanding Shares
50,321,000
Free Float
45,727,000
Market Cap
$458.93 million
Optionable
Optionable
Beta
1.53

Social Links

7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Michael D. Clayman
    President, Chief Executive Officer & Director
  • Fred Driscoll
    Chief Financial Officer
  • William T. Andrews
    Chief Medical Officer
  • Carolyn Beaty Scimemi
    Chief Compliance Officer & Head-Legal Affairs
  • Christina WillwerthChristina Willwerth
    Chief Strategy Officer

Key Competitors

View All Competitors














FLXN Stock Analysis - Frequently Asked Questions

How were Flexion Therapeutics' earnings last quarter?

Flexion Therapeutics, Inc. (NASDAQ:FLXN) issued its quarterly earnings data on Wednesday, May, 12th. The specialty pharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.08. The specialty pharmaceutical company had revenue of $24.59 million for the quarter, compared to analysts' expectations of $24.61 million.

What is Mike Clayman, MD's approval rating as Flexion Therapeutics' CEO?

46 employees have rated Flexion Therapeutics Chief Executive Officer Mike Clayman, MD on Glassdoor.com. Mike Clayman, MD has an approval rating of 85% among the company's employees.

What other stocks do shareholders of Flexion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Cara Therapeutics (CARA), Aduro Biotech (ADRO), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX) and Verastem (VSTM).

This page (NASDAQ:FLXN) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -